EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access · CC BY-NC-ND 4.0

Trends in Primary Biliary Cholangitis: Prospective Cohort Study From the European Reference Network Registry (R‐LIVER)

A Gerussi, E Nofit, D P Bernasconi iD, C Kroll, F Groß, I Schregel, A Marini, L Cristoferi iD, F Malinverno, M Papp iD, G Dalekos iD, E Rigopoulou iD und 12 weitere

United European Gastroenterology Journal · 2025

DOI: 10.1002/ueg2.70134 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift United European Gastroenterology Journal, 2025. Verfasst von A Gerussi und 23 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Autoimmune Liver Diseases and Division of Gastroenterology, European Reference Network (ERN) RARE-LIVER, Fondazione IRCCS San Gerardo dei …. Hauptthemen laut MEDLINE: Ursodeoxycholic Acid, Liver Cirrhosis, Biliary, Cholagogues and Choleretics. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: R-LIVER registry.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims The European Reference Network on Hepatological Diseases (ERN RARE‐LIVER) is a Europe‐wide network for centers of excellence in the management of rare liver diseases. We aimed to evaluate the current diagnostic and therapeutic trends of primary biliary cholangitis (PBC).

Methods

Prospective data of PBC cases diagnosed from 2017 to March 2024 were extracted from the R‐LIVER registry of ERN‐RARE LIVER. Cases without two follow‐ups within 24 months were excluded from the treatment analysis. Biochemical response according to Toronto criteria and normalization of alkaline phosphatase (ALP) values after 12 months of Ursodeoxycholic Acid (UDCA) were evaluated.

Results

This study included 327 incident cases from six centers. Median age was 56 years, 89.3% were female. At the time of diagnosis, median values of ALP were 1.37 x ULN, and median bilirubin was 0.49 x ULN. Transient elastography (TE) was performed in 230 patients (70.3%) at baseline; median liver stiffness was 6.2 kPa. Out of 316 subjects, treatment with UDCA was started in 312 patients (98.7%); 246 (85.1%) achieved ALP values < 1.67 x ULN at 12 months. Normalization of ALP values occurred in 143 subjects (49.5%) at 12 months. Among 43 patients with inadequate response, 18 (41.9%) were treated with second‐line therapies, and had worse liver biochemistry at baseline.

Conclusion

In the current era, patients with PBC are diagnosed at an early stage using non‐invasive methods and are almost all treated with UDCA. The biochemical response rate is 85.1%, but the use of second‐line therapies for inadequate responders remains suboptimal.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ursodeoxycholic AcidLiver Cirrhosis, BiliaryCholagogues and CholereticsHumansFemaleMaleMiddle AgedRegistriesProspective StudiesEuropeAlkaline PhosphataseAgedAdultElasticity Imaging TechniquesLiverTreatment Outcome

Stichwörter der Autor:innen

UDCAautoimmunitycholestasisepidemiologyliver

Substanzen

Ursodeoxycholic AcidAlkaline PhosphataseCholagogues and Choleretics

Autor:innen und Institutionen

  • Centre for Autoimmune Liver Diseases and Division of Gastroenterology, European Reference Network (ERN) RARE-LIVER, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
  • Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
  • Department of Medicine, University Medical Centre Hamburg-Eppendorf (UKE), Hamburg, Germany.
  • European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Hamburg, Germany.
  • Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Hungary, Germany.
  • Department of Medicine and Research Laboratory of Internal Medicine, National Expertise Center of Greece in Autoimmune Liver Diseases, General University Hospital of Larissa, Larissa, Greece.

ORCID-Profile: D P Bernasconi, L Cristoferi, M Papp, G Dalekos, E Rigopoulou, M K Janik, H Ytting, C Casar, A Lohse, M Carbone, C Schramm, P Invernizzi

Förderung

  • R-LIVER registry

Zitieren

APA

Gerussi, A., Nofit, E., Bernasconi, D. P., Kroll, C., Groß, F., Schregel, I., Marini, A., Cristoferi, L., Malinverno, F., Papp, M., Dalekos, G., Rigopoulou, E., Janik, M. K., Milkiewitz, P., Ytting, H., Leburgue, A., Braun, F., Casar, C., Sebode, M., …, & Invernizzi, P. (2025). Trends in Primary Biliary Cholangitis: Prospective Cohort Study From the European Reference Network Registry (R‐LIVER). United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.70134

Vancouver

Gerussi A, Nofit E, Bernasconi DP, Kroll C, Groß F, Schregel I, et al. Trends in Primary Biliary Cholangitis: Prospective Cohort Study From the European Reference Network Registry (R‐LIVER). United European Gastroenterology Journal. 2025. doi:10.1002/ueg2.70134

BibTeX
@article{Gerussi2025,
  author = {Gerussi, A and Nofit, E and Bernasconi, D P and Kroll, C and Groß, F and Schregel, I and Marini, A and Cristoferi, L and Malinverno, F and Papp, M and Dalekos, G and Rigopoulou, E and Janik, M K and Milkiewitz, P and Ytting, H and Leburgue, A and Braun, F and Casar, C and Sebode, M and Lohse, A and Hansen, B and Carbone, M and Schramm, C and Invernizzi, P},
  title = {Trends in Primary Biliary Cholangitis: Prospective Cohort Study From the European Reference Network Registry (R‐LIVER)},
  journal = {United European Gastroenterology Journal},
  year = {2025},
  doi = {10.1002/ueg2.70134}
}
Kostenlos starten →